FDA Warning Letter to Amie Health Cites Compounded GLP-1 Labeling and "FDA-Approved Active Ingredients" Claims
On June 8, 2026, FDA issued a warning letter to Amie Health, Inc. dba Amie after a March 2026 review of tryamie.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "amie" as if the company were the compounder "when in fact it is not," and cites claims including "Ozempic, Mounjaro, and Wegovy contain the same active ingredients as our compounded versions" and "All our treatments use FDA-approved active ingredients," which FDA says falsely imply FDA approval. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
Source: FDA original ↗